RankAlpha logo
Back to Rankings

PODD

InsuletF
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
View Chart
Current thesis
Primary-source earnings evidence was strong: revenue growth exceeded guidance, operating margin expanded, free cash flow rose to $89.5 million, and FY2026 revenue guidance was raised. The operating story is still centered on Omnipod adoption, especially international, with additional pipeline optionality from type 2 AID.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +8.4.
What can break
Direct diabetes-technology competition from Tandem and Medtronic can pressure new-user acquisition, retention, pricing, and the perceived differentiation of tubeless AID over time.
Momentum
3
Value
56
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $172.00 · Bull $205.00 · Bear $130.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $357.64
Why
Momentum3 · Δ7d -0.3
Value56 · Δ7d +0.4
Sentiment56 · Δ7d +8.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
3
34% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
+0.5
Value
56
32% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+1.2
Sentiment
56
33% active weight
Current posture
7d trendImproving
Δ7d
+8.4
Δ21d
+13.0
Why this grade

Composite grade F. Momentum 3.3 / Value 55.6 / Sentiment 55.7

Fundamentals (TTM)
As of 2026-05-29
Market Cap
$10.04B
Beta
1.41
Shares Out
70.35M
P/E (TTM)
82.3
P/S (TTM)
7.91
P/FCF (TTM)
48.92
Rev YoY
+29.9%
EPS YoY
+14.9%
Gross Margin
+71.5%
Op Margin
+12.4%
Net Debt
$438.7M
Current Ratio
2.87
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology